Please login to the form below

Not currently logged in
Email:
Password:

Dr Thomas Lynch Jnr takes up new role at Bristol-Myers Squibb

Will focus on leading the firm's research and development programme

Dr Thomas Lynch JnrBristol-Myers Squibb (BMS) has appointed Dr Lynch as executive vp and chief scientific officer, a role that will see him focus on leading the firm’s research and development programme.

He previously served on the firm's board of directors and succeeds Dr Francis Cuss who will retire from the company.

Dr Lynch said: “I have seen first-hand Bristol-Myers Squibb’s commitment to making a meaningful difference in the lives of patients, and I am honoured to lead the company’s R&D programme.

“I am confident that our team will continue to discover and develop innovative medicines that address serious diseases in areas of significant unmet medical need.”

Dr Lynch has more than 30 years medical, management and leadership experience and joined BMS in 2013 from the Yale Cancer Center.

Giovanni Caforio, chief executive officer at Bristol-Myers Squibb, added: “Tom brings deep industry knowledge and a sophisticated understanding of the Bristol-Myers Squibb research and development programme from his experience as a member of our Board.

“As we transition to our next phase of growth, we are confident Tom is the right person to lead our dynamic R&D organisation as we focus on accelerating the development of our immuno-oncology medicines.”

28th March 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics